- Home
- / Adagio Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Adagio Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$3.5
2022-11-14
Market Capitalization
$516.2 M
2022-11-14
Revenue
$53.4 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 25.4M | 53.4M | |||
| General and administrative expense | 36.5M | 47.0M | 49.1M | 63.4M | 66.9M |
| Operating expense total | 226.3M | 207.8M | 200.6M | 105.2M | |
| EBIT | (226.9M) | (248.0M) | (212.8M) | (176.9M) | (55.6M) |
| EBIT margin, % | -696.8% | -104.0% | |||
| Interest expense | 7.2M | 3.1M | |||
| Net Income | (226.8M) | (241.3M) | (198.6M) | (169.9M) | (52.5M) |
| EPS | (2.2) | (1.8) | (1.4) | (0.3) |